1. Scrip
  2. >>New Products

Reprioritization On Cards After Sage/Biogen’s Zurzuvae Receives CRL For MDD

Despite PPD Approval

 
• By Ayisha Sharma

The firms’ Zurzuvae has become the first oral drug to win US approval for postpartum depression but a thumbs down in the larger major depressive disorder indication has raised concerns that Biogen could pull out of the partnership as Sage turns its efforts to cutting costs.  

woman sitting on floor with head down next to baby in crib
PPD Affects Around 500,000 Women In The US • Source: Shutterstock
Key Takeaways:

  • Zurzuvae was approved in PPD but with the caveat of black box warnings that could limit uptake.

  • The CRL in MDD surprised most analysts as the pivotal WATERFALL trial had met its primary endpoint.

  • Sage is planning a reprioritization that could include pipeline and job cuts with further details to come.

Sage Therapeutics, Inc./Biogen, Inc

The FDA approved 50mg Zurzuvae as the first oral, once-daily, 14-day treatment for PPD based on data from the pivotal NEST program

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.